Navigation Links
Sanofi US Launches Collaborate Activate Innovation Challenge
Date:7/23/2012

BRIDGEWATER, N.J., July 23, 2012 /PRNewswire/ -- Sanofi US today launched the Collaborate Activate Innovation Challenge, which will award a total of $500,000 to teams of patient advocacy groups and/or medical professional associations who deliver novel approaches to better engage patients in their own health. Based on the concept that advocates working together can make a bigger collective impact than groups working alone, the Challenge requires groups to collaborate to qualify for the contest.

"To achieve successful health outcomes, the patient must be actively engaged in his or her own health," said Anne Whitaker, President North America Pharmaceuticals at Sanofi US. "With patients spending on average only a few hours in a doctor's office a year, successful management of any health condition goes beyond the physician and requires positive impact from the groups that support the patient - from caregivers to patient advocates to providers. Sanofi US is pleased to present the Collaborate Activate Innovation Challenge to promote collaboration between the key patient influencers to help identify new ways to encourage patient engagement, to help patients navigate their journey with their condition, and ultimately to improve the patients' health outcomes."

The Innovation Challenge is designed to foster collaboration between non-profit organizations with a common purpose and promote sharing of complementary resources to accelerate the impact on people's health. To support this idea, the entries must meet these parameters:

  • Proposed ideas must focus on engaging people to take an active role in their healthcare
  • Submissions must include two or more non-profit patient advocacy groups and/or medical professional organizations; a multidisciplinary approach is highly encouraged

Four finalist teams will receive opportunities for mentorship to fully optimize impact and outcomes. At a Finalist Event, the four teams will present their plans to a panel of expert judges and a winning team and runner-up will be selected.

The Collaborate Activate Innovation Challenge awards totalling $500,000 will be distributed as follows:

  • Four finalist teams will be selected and will each receive $25,000
  • From the four teams, one runner-up will receive an additional $100,000
  • One winning team will receive an additional $300,000

Submissions will be accepted July 23 through August 31, 2012. Finalists will be announced on September 17 and the winner will be announced on November 15, 2012.

For a complete list of Challenge rules, and to submit a concept, visit: www.collaborateactivate.com.

To follow the Challenge as it progresses, follow us:

Sanofi US "Partners in Patient Health"

The Collaborate Activate Innovation Challenge is an initiative of Sanofi US's Partners in Patient Health team, which is leading a novel approach to partnering with the advocacy community by connecting people, ideas, and solutions to focus on critical issues that are of high importance and common across a wide range of advocates dedicated to advancing patient health. 

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi is the holding company of a consolidated group of subsidiaries and operates in the United States as Sanofi US. For more information on Sanofi US, please visit http://www.sanofi.us or call 1-800-981-2491.

Sanofi US is also on Twitter and Facebook. Visit us at https://twitter.com/SanofiUS and http://www.facebook.com/sanofiUS.

Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2010. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Contacts:

Media Relations
Jack Cox
Tel.: 908 981 5280
Jack.cox@sanofi.com

US.GLA.12.07.045 


'/>"/>
SOURCE Sanofi
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
2. Berg Pharma launches clinical trial on BPM 31543 for prevention of chemotherapy-induced alopecia (CIA)
3. Ellman International Launches Multi-stage Growth Plan With Acquisition Of Sandstone Medical Technologies
4. Siemens Launches Next Generation Automation Solution Aptio at AACC 2012
5. Gentris Corporation Launches New Pharmacogenomics Services
6. Bath Salts: With Dangerous Drug Use on the Rise, Ameritox Launches Critical New Test to Help Detect Designer Drug
7. Neutronic Ear Launches Informative Knowledge Sharing Website
8. WaferGen Bio-systems Launches MyDesign - Setting a New Standard in Flexibility with an Open Format High-Throughput qPCR Platform
9. Nouveau Life Pharmaceuticals (NOUV) Launches Affiliate Sales Program
10. Marken Launches New Global Regulatory Consultation Services
11. Ulthera Launches New Aesthetic Clinical Indication - Treatment of the Decolletage - in Asia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop ... The fitness app plans to fix the two major problems leading the fitness industry today:, ... all type program , They don’t eliminate all the reasons people quit their ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
Breaking Medicine News(10 mins):